Related Experiment Video

Updated: Mar 27, 2026

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

3.4K

Targeting translation: eIF4E as an emerging anticancer drug target

Chunwan Lu1, Levi Makala2, Daqing Wu2

  • 1College of Life Sciences,Anhui Normal University,Key Laboratory of Biotic Environment and Ecological Safety in Anhui Province,Wuhu 241000,Anhui,China.

Expert Reviews in Molecular Medicine
|January 19, 2016
PubMed

Insights

Targeting eukaryotic initiation factor 4E (eIF4E) offers a promising anticancer strategy by inhibiting the translation of key oncoproteins. This review explores diverse methods to block eIF4E activity and combat cancer progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Eukaryotic initiation factor 4E (eIF4E) is a critical regulator of cap-dependent translation.
  • Selective translation of oncoproteins like cyclin D1, survivin, and VEGF by eIF4E drives tumor growth, metastasis, and therapy resistance.
  • eIF4E acts as a central hub where oncogenic signaling pathways converge.

Purpose of the Study:

  • To review strategies for targeting eIF4E-mediated cap-dependent translation as an anticancer approach.
  • To highlight agents that inhibit eIF4E activity at various regulatory levels.

Main Methods:

  • Literature review of existing and emerging therapeutic strategies targeting eIF4E.
  • Analysis of distinct molecular mechanisms to inhibit eIF4E function.
  • Categorization of agents based on their mode of action against eIF4E.

Main Results:

  • eIF4E's crucial role in cancer progression is confirmed.
  • Multiple strategies exist to target eIF4E, including direct inhibition and disruption of its interactions.
  • Agents targeting eIF4E show potential in preclinical and clinical settings.

Conclusions:

  • Targeting eIF4E-mediated translation is a viable and promising anticancer strategy.
  • A comprehensive understanding of targeting strategies is essential for developing effective cancer therapies.
  • Further research into novel eIF4E inhibitors is warranted.

More Related Videos

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis09:58

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Published on: June 27, 2020

3.2K
Xenopus laevis as a Model to Identify Translation Impairment10:24

Xenopus laevis as a Model to Identify Translation Impairment

Published on: September 27, 2015

11.2K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
67
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.8K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.5K